SCAI 2026 Workshop on the Treatment of Pulmonary Embolism-On the Horizon: Clinical Trials That May Impact Future Guidelines, Dr. Sethi

On the Horizon: Clinical Trials That May Impact Future Guidelines, Dr. Sethi

Video Transcription

Video Summary

The speaker discussed how upcoming pulmonary embolism trials may shape future treatment guidelines, especially for high-risk and intermediate-high-risk PE. In high-risk PE with shock, multiple 2A options exist, including systemic thrombolysis, catheter-directed therapy, mechanical thrombectomy, and surgery. Ongoing trials like PERSEVERE and TORPEDO may strengthen evidence for thrombectomy. For intermediate-high-risk PE, current data show catheter therapies quickly improve right ventricular strain and are generally safe, but mortality benefit remains unproven. Future studies such as PEERLESS II, PE-TRACT, and PYTHO 3 aim to clarify who benefits, which endpoints matter, and whether treatments improve long-term outcomes like post-PE syndrome.

Asset Caption

closed captions are computer-generated

Keywords

pulmonary embolism trials

high-risk PE

intermediate-high-risk PE

catheter-directed therapy

mechanical thrombectomy